IL-33 Antikörper

Produktnummer ABIN1169165

Der Kaninchen Polyklonal Anti-IL-33-Antikörper wurde für WB, ELISA und IHC validiert. Er ist geeignet, IL-33 in Proben von Human zu detektieren. Es ist 1 Publikation verfügbar.

Kurzübersicht für IL-33 Antikörper (ABIN1169165)

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IL-33 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktdetails anti-IL-33 Antikörper

Spezifität: Recognizes human IL-33. Detects a band of ~18 kDa by Western blot.

Kreuzreaktivität: Human

Sterilität: 0.2 μm filtered

Immunogen: Recombinant human IL-33.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 6 months after receipt when stored at -20°C.

Haltbarkeit: 6 months

Referenzen für anti-IL-33 Antikörper (ABIN1169165)

Carriere, Roussel, Ortega, Lacorre, Americh, Aguilar, Bouche, Girard: "IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, Issue 1, pp. 282-7, (2007) (PubMed).

Details zu IL-33

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Andere Bezeichnung: IL-33

Hintergrund: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1(MAPK3)/ERK2(MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

UniProt: O95760

Pathways: Production of Molecular Mediator of Immune Response